A. Manouchehrinia's Profile

Role	Title	Level	Year	L/R
🐜	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study 52 auth. P. Benkert, S. Meier, S. Schaedelin, A. Manouchehrinia, Ö. Yaldizli, A. Maceski, J. Oechtering, L. Achtnichts, D. Conen, T. Derfuss, P. Lalive, C. Mueller, S. Müller, Y. Naegelin, J. Oksenberg, ... C. Pot, A. Salmen, E. Willemse, I. Kockum, K. Blennow, H. Zetterberg, C. Gobbi, L. Kappos, H. Wiendl, Klaus Berger, M. Sormani, C. Granziera, F. Piehl, D. Leppert, J. Kuhle, S. Aeschbacher, M. Barakovic, A. Buser, A. Chan, G. Disanto, M. D’Souza, R. Pasquier, O. Findling, R. Galbusera, K. Hrusovsky, M. Khalil, Johannes Lorscheider, A. Mathias, A. Orleth, E. Radue, R. Rahmanzadeh, T. Sinnecker, Suvitha Subramaniam, J. Vehoff, S. Wellmann, J. Wuerfel, C. Zecca	8	2022	8 🐜
🦁	Confounding effect of blood volume and body mass index on blood neurofilament light chain levels 7 auth. A. Manouchehrinia, F. Piehl, J. Hillert, J. Kuhle, L. Alfredsson, T. Olsson, ... I. Kockum	7	2020	7 🦁
🦁	Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study A. Manouchehrinia, C. Tench, J. Maxted, Rashid H. Bibani, J. Britton, C. Constantinescu	7	2013	7 🦁
🐜	Effect of Smoking Cessation on Multiple Sclerosis Prognosis. 7 auth. Ryan Ramanujam, A. Hedström, A. Manouchehrinia, L. Alfredsson, T. Olsson, M. Bottai, ... J. Hillert	7	2015	7 🐜
🐜	Importance of early treatment initiation in the clinical course of multiple sclerosis 9 auth. A. Kavaliunas, A. Manouchehrinia, L. Stawiarz, Ryan Ramanujam, Jonas Agholme, A. Hedström, ... O. Beiki, A. Glaser, J. Hillert	7	2017	7 🐜
🦁	Age Related Multiple Sclerosis Severity Score: Disability ranked by age 11 auth. A. Manouchehrinia, Helga Westerlind, E. Kingwell, F. Zhu, R. Carruthers, Ryan Ramanujam, ... M. Ban, A. Glaser, S. Sawcer, H. Tremlett, J. Hillert	6	2017	6 🦁
🐜	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response 47 auth. T. Kalincik, A. Manouchehrinia, L. Sobíšek, V. Jokubaitis, T. Spelman, D. Horáková, E. Havrdová, M. Trojano, G. Izquierdo, A. Lugaresi, M. Girard, A. Prat, P. Duquette, P. Grammond, P. Sola, ... R. Hupperts, F. Grand'Maison, E. Pucci, C. Boz, R. Alroughani, V. van Pesch, J. Lechner-Scott, M. Terzi, R. Bergamaschi, G. Iuliano, F. Granella, D. Spitaleri, V. Shaygannejad, C. Oreja-Guevara, M. Slee, R. Ampapa, F. Verheul, P. Mccombe, J. Olascoaga, M. Amato, S. Vucic, S. Hodgkinson, C. Ramo-Tello, S. Flechter, E. Cristiano, C. Rozsa, F. Moore, J. Sánchez-Menoyo, M. Saladino, M. Barnett, J. Hillert, H. Butzkueven	6	2017	6 🐜
🦁	Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios A. Manouchehrinia, R. Tanasescu, C. Tench, C. Constantinescu	6	2015	6 🦁
🐜	Blood neurofilament light levels segregate treatment effects in multiple sclerosis 16 auth. B. Delcoigne, A. Manouchehrinia, Christian Barro, P. Benkert, Z. Michalak, L. Kappos, D. Leppert, J. Tsai, T. Plavina, B. Kieseier, ... J. Lycke, L. Alfredsson, I. Kockum, J. Kuhle, T. Olsson, F. Piehl	6	2020	6 🐜
🐜	Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies 8 auth. N. Dunn, A. Juto, M. Ryner, A. Manouchehrinia, L. Piccoli, K. Fink, ... F. Piehl, A. Fogdell-Hahn	6	2018	6 🐜